Lung cancer immunotherapy is moving beyond PD-L1 alone
Immune checkpoint inhibitors have changed lung cancer care in ways that were difficult to imagine a decade ago. Their role now reaches pretreated non-small cell lung cancer, first-line metastatic disease, locally advanced settings, and even early-stage disease, yet patient selection still leans heavily on a single imperfect biomarker: PD-L1 tumor expression. The problem is not lack of clinical utility. The problem is biological incompleteness. PD-L1 captures only one slice of a much larger immune interaction between tumor cells, host immunity, and the treatment environment that determines whether a patient benefits from an immune checkpoint inhibitor or develops toxicity without meaningful gain.
A biomarker that is too narrow cannot carry the weight of modern immuno-oncology. In lung cancer, that limitation is especially stark because disease biology varies across histology, stage, prior treatment exposure, and immune contexture. The editorial places this challenge at the center of the field: treatment has advanced faster than predictive precision. The result is a widening gap between therapeutic capability and the ability to identify, up front, who is most likely to respond.
Why PD-L1 remains useful but insufficient
The editorial makes clear that PD-L1 tumor proportion score remains the only approved predictive factor used to guide selection for these agents. Yet even in routine practice, PD-L1 alone leaves major uncertainty in both directions. Some patients with high expression do not respond, while others with low or absent expression still derive benefit. Tumor staining also reflects a static measurement taken at one point in time, while immune escape evolves under treatment pressure, clonal selection, and changes in the tumor microenvironment.
That mismatch explains why the field keeps searching for better indicators of response and resistance. The clinical stakes are concrete. If prediction improves, unnecessary exposure to expensive therapy and immune-related toxicity falls. If prediction fails, clinicians still face the same familiar uncertainty: whether to continue, escalate, combine, or switch treatment after the first signs of resistance appear.
The discussion is especially relevant in small cell lung cancer, where use of immune checkpoint inhibitors in extensive-stage or limited-stage disease is not driven by PD-L1 status or any other validated biomarker. In that setting, the gap between biologic rationale and clinical stratification is even wider.
Blood-based signals may offer a faster read on treatment biology
Circulating biomarkers carry obvious appeal because they are minimally invasive, repeatable, and often inexpensive. The editorial points to several examples already under active study, including the derived neutrophil-to-lymphocyte ratio, lactate dehydrogenase, and the Lung Immune Prognostic Index. These measures do not directly map immune recognition of tumor antigens, but they reflect systemic inflammatory tone, tumor burden, and the host response that can shape immunotherapy outcomes.
A single blood draw may not outperform tissue-based profiling, but serial blood testing can reveal movement over time. Absolute lymphocyte count and circulating cytokine patterns may show whether the immune system is being suppressed, mobilized, or exhausted during treatment. In a disease where response can shift after just a few cycles of therapy, dynamic sampling may be more informative than one static biopsy.
LDH remains biologically plausible as a marker of tumor glycolysis and aggressive disease behavior. Neutrophil-heavy inflammatory states may signal an immunosuppressive milieu, while relative lymphopenia may reflect reduced immune reserve. Those signals are indirect, but they are not random. They point toward the biology that determines whether checkpoint blockade can actually re-activate an antitumor response.
The microbiome is emerging as a treatment modifier
The microbiome has become one of the most compelling new variables in immunotherapy response. Across solid tumors, including lung cancer, gut microbial composition appears to influence how the immune system reacts to checkpoint blockade. The editorial also notes a practical complication: antibiotics and proton pump inhibitors can alter the microbiome, and by extension may affect treatment outcomes.
This is a biologically plausible mechanism rather than a speculative flourish. The gut ecosystem helps shape immune tone, antigen presentation, and inflammatory signaling. If that ecosystem is disrupted, the downstream immune response may become less coordinated. Fecal microbiota transplantation has already been reported as a potential way to modify immunotherapy efficacy, and that line of inquiry signals how far the field has moved from a tumor-only model of treatment response.
The next step is integration, not substitution
The editorial does not argue for abandoning PD-L1. It argues for building a broader framework around it. Tumor genomics, transcriptomics, liquid biopsies, the tumor microenvironment, and the microbiome each contribute a different layer of predictive information. No single marker is likely to explain the full range of response and resistance in lung cancer. The more realistic goal is integration: combining biologic layers into composite models that can support clinical decisions with greater confidence than any one assay can offer.
That approach fits the current state of immuno-oncology. Resistance emerges through multiple routes, including immune exclusion, antigen presentation failure, myeloid suppression, and microbiome-related modulation of systemic immunity. A unified biomarker strategy has to reflect that complexity. Tissue may show one thing, blood another, and the microbiome yet another. The challenge is to determine which combination best predicts response before treatment starts and which patterns change when resistance develops.
A Research Topic that mirrors the field’s rapid expansion
The Research Topic brought together 19 articles, including original studies, systematic reviews, literature reviews, and case reports, with more than 130 authors contributing across countries. That volume reflects how quickly this question has expanded beyond a narrow biomarker debate. Lung cancer immunotherapy now sits at the intersection of translational science, molecular pathology, and real-world treatment selection.
This editorial frames the collection as part of a broader shift away from a PD-L1-centric model. The field is no longer asking whether checkpoint inhibitors work. That question has already been answered. The more urgent question is which patients are biologically primed to benefit, which are destined for primary resistance, and which may need combinations or alternative strategies from the outset.
One line in the editorial is especially important in clinical terms: future validation must be prospective. Retrospective associations and exploratory signals can generate hypotheses, but they do not yet provide the level of certainty needed to steer first-line lung cancer treatment across diverse practice settings. Without prospective confirmation, biomarker enthusiasm can outpace real-world reliability.
The next generation of immunotherapy biomarkers will need to prove that they can do more than correlate with outcome. They will need to change treatment choices, reduce avoidable toxicity, and survive validation across histology, stage, and treatment context. Until then, PD-L1 remains useful, but it is still only the starting point.